Health Canada Permits Physicians to Prescribe Psyc
Post# of 341
(Total Views: 240)
Posted On: 01/14/2022 6:05:48 PM
Health Canada Permits Physicians to Prescribe Psychedelic Drugs for Mental Illnesses
The Special Access Program by Health Canada allows patients with life-threatening mental health conditions whose previous treatments have been ineffective to begin using MDMA and psilocybin mushrooms as part of their treatment. Before physicians were allowed to prescribe these medicines, the drugs could only be used after an exemption was granted for individual palliative cases by Health Canada.
David Harder states that this move, which allows physicians to prescribe psychedelics in their practices, is a huge shift with regard to psychedelic legalization in Canada. Harder, who operates the ATMA Calgary Urban Journey Center, added that physicians would still be required to make their prescriptions in an individualized and controlled fashion. He also noted that the steady liberalization of the medical use of psychedelic drugs was indisputable.
Dr. Robert Tanguay agrees with Harder, as there’s a lot of evidence showing how these drugs enhance and improve people’s mental health. The doctor operates the Newly Institute in Calgary, which uses psychedelic drugs to treat mental disorders. Tanguay explained how psychedelic drugs such as psilocybin deconstruct psychological barriers that patients who suffer from mental illnesses such as depression or post-traumatic stress disorder had erected.
He added that while psychedelics did possess potent properties, the substances couldn’t be administered alone and had to be used in conjunction with more standard supervised therapy. Tanguay revealed that the Newly Institute saw roughly 35 clients every month, many of whom were undergoing a treatment regimen that involved the use of ketamine. In addition to this, Tanguay stated that he looked forward to pushing the boundaries of psychedelic therapy through the use of substances including ayahuasca and LSD.
Dr. John Huber, CEO of the Tripsitter Clinic, revealed that he hoped this decision by Ottawa would expand access to psilocybin and MDMA therapy and save the lives of patients suffering from various life-threatening mental illnesses. The Tripsitter clinic uses ketamine in its treatments and is based in the United States. Huber added that he hoped Canada’s success would prompt the U.S. government to follow suit, as many in the U.S. are waiting for approval for psilocybin and MDMA from the FDA.
The ATMA Calgary Urban Journey Center is set to begin its first clinical trial after receiving a no-objection letter from Health Canada. The trial’s objective is to evaluate the safety of synthetic psychedelics. It will recruit therapists as participants who will be required to ingest psychedelics in the company of a pair of colleagues in a session that lasts about six hours. The exercise will also provide hands-on training for therapists.
The growing acceptance of psychedelic therapeutics by health authorities in different jurisdictions is testament to how far the research and development activities of entities such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) have gone to change societal perceptions about the medicinal potential of psychedelic compounds.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
The Special Access Program by Health Canada allows patients with life-threatening mental health conditions whose previous treatments have been ineffective to begin using MDMA and psilocybin mushrooms as part of their treatment. Before physicians were allowed to prescribe these medicines, the drugs could only be used after an exemption was granted for individual palliative cases by Health Canada.
David Harder states that this move, which allows physicians to prescribe psychedelics in their practices, is a huge shift with regard to psychedelic legalization in Canada. Harder, who operates the ATMA Calgary Urban Journey Center, added that physicians would still be required to make their prescriptions in an individualized and controlled fashion. He also noted that the steady liberalization of the medical use of psychedelic drugs was indisputable.
Dr. Robert Tanguay agrees with Harder, as there’s a lot of evidence showing how these drugs enhance and improve people’s mental health. The doctor operates the Newly Institute in Calgary, which uses psychedelic drugs to treat mental disorders. Tanguay explained how psychedelic drugs such as psilocybin deconstruct psychological barriers that patients who suffer from mental illnesses such as depression or post-traumatic stress disorder had erected.
He added that while psychedelics did possess potent properties, the substances couldn’t be administered alone and had to be used in conjunction with more standard supervised therapy. Tanguay revealed that the Newly Institute saw roughly 35 clients every month, many of whom were undergoing a treatment regimen that involved the use of ketamine. In addition to this, Tanguay stated that he looked forward to pushing the boundaries of psychedelic therapy through the use of substances including ayahuasca and LSD.
Dr. John Huber, CEO of the Tripsitter Clinic, revealed that he hoped this decision by Ottawa would expand access to psilocybin and MDMA therapy and save the lives of patients suffering from various life-threatening mental illnesses. The Tripsitter clinic uses ketamine in its treatments and is based in the United States. Huber added that he hoped Canada’s success would prompt the U.S. government to follow suit, as many in the U.S. are waiting for approval for psilocybin and MDMA from the FDA.
The ATMA Calgary Urban Journey Center is set to begin its first clinical trial after receiving a no-objection letter from Health Canada. The trial’s objective is to evaluate the safety of synthetic psychedelics. It will recruit therapists as participants who will be required to ingest psychedelics in the company of a pair of colleagues in a session that lasts about six hours. The exercise will also provide hands-on training for therapists.
The growing acceptance of psychedelic therapeutics by health authorities in different jurisdictions is testament to how far the research and development activities of entities such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) have gone to change societal perceptions about the medicinal potential of psychedelic compounds.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼